Recent Company News

• 05:21 PM ET Jun 27, 2025
  

  NuCana enters into a sales agreement of up to $100.0M with A.G.P. and Laidlaw & Company - 424B5 ($0.09, 0.00)

• 04:04 PM ET Jun 02, 2025
  

  NuCana reports Q1 EPS (2p) vs FactSet (1p) [1 est] ($0.04, 0.00)

• 08:32 AM ET May 06, 2025
  

  NuCana announces pricing of $7M registered direct offering through Laidlaw ($1.10, 0.00)

• 01:49 PM ET Apr 29, 2025
  

  NuCana files amended F-1; to offer up to ~12.5M ADSs/pre-funded warrants, Series A warrants, and Series B warrants through Laidlaw ($0.54, -0.02)

• 06:17 AM ET Apr 24, 2025
  

  NuCana files to offer up to 16.0M ADSs and/or pre-funded warrants through Laidlaw - F-1 ($0.89, 0.00)

• 04:08 PM ET Mar 20, 2025
  

  NuCana reports Q4 EPS (£0.01) vs year-ago (£0.14) ($0.81, 0.00)

• 07:06 AM ET Nov 25, 2024
  

  NuCana reports Q3 EPS (£0.07) vs. (£0.13) ($1.23, 0.00)

• 07:04 AM ET Nov 11, 2024
  

  NuCana announces initial data from Phase 1B/2 modular study of NUC-3373 in combination with Pembrolizumab or Docetaxel ($1.51, 0.00)

• 05:58 PM ET Sep 25, 2024
  

  StreetAccount Summary - After-hours trading update

• 04:29 PM ET Sep 25, 2024
  

  StreetAccount Summary - After-hours trading